

PRIOR AUTHORIZATION REQUEST

<u>Filsuvez</u>

Patient Information	:			
Name:				
Member ID:				
Address:				
City, State, Zip:				
Date of Birth:				
1				
Prescriber Informa	tion:			
Name:				
NPI:				
Phone Number:				
Fax Number				
Address:				
City, State, Zip:				
Requested Medicat	ion			
Rx Name:				
Rx Strength				
Rx Quantity:				
Rx Frequency:				
Rx Route of				
Administration:				
Diagnosis and ICD	Code:			
prescribed a medication quantities can be provided upon receipt of the	on for your rided. Plea completed	efit requires that we review certain requests for coverage with the proposition patient that requires Prior Authorization before benefit coverage or consections the following questions then fax this form to the toll-free not form, prescription benefit coverage will be determined based on the that supporting clinical documentation is required.	verage of number lis the plar	f additional ted below. n's rules.
1 Is the pat [If no, ski		ntly receiving the requested medication? ion 8.]	Yes	No
•	Has the patient been receiving medication samples of Filsuvez? [If yes, skip to question 8.]		Yes	No
the currer [Note: If t	nt plan for ne patient I medicati ial therap		Yes	No

PRIOR AUTHORIZATION REQUEST

4	Has the patient been established on therapy for at least 3 months? [If no, skip to question 8.]	Yes	No
5	Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
6	What is the indication or diagnosis? [] Dystrophic epidermolysis bullosa (If checked, go to 7)		
	[] Junctional epidermolysis bullosa (If checked, go to 7)		
	[] Other (If checked, no further questions)		
7	Is the requested medication prescribed by or in consultation with a dermatologist or wound care specialist? [No further questions.]	Yes	No
8	Is the patient at least 6 months of age and older? [If no, no further questions.]	Yes	No
9	What is the indication or diagnosis? [] Dystrophic epidermolysis bullosa (If checked, go to 10)		
	[] Junctional epidermolysis bullosa (If checked, go to 11)		
	[] Other (If checked, no further questions)		
10	Has the patient had a trial and failure (for at least 90 days), contraindication to, or intolerance to Vyjuvek (beremagene geperpavec-svdt)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
11	Does the patient have a documented diagnosis of dystrophic epidermolysis bullosa or junctional epidermolysis bullosa confirmed by genetic testing? [If no, no further questions.]	Yes	No
12	Is the target wound(s) 10 cm2 to 50 cm2? [If no, no further questions.]	Yes	No
13	Is the target wound(s) greater than or equal to 21 days and less than 9 months old? [If no, no further questions.]	Yes	No
14	Does the target wound(s) appear to be infected?	Yes	No



PRIOR AUTHORIZATION REQUEST

	[If yes, no further questions.]		
15	Has squamous cell and/or basal cell carcinoma been ruled out for the target wound(s)? [If no, no further questions.]	Yes	No
16	Is the requested medication prescribed by or in consultation with a dermatologist or wound care specialist?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B

Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.